Ten63 Therapeutics Launches BEYOND-Alpha, with Chugai Pharmaceutical as First Participant

PR Newswire
Today at 5:10pm UTC

Ten63 Therapeutics Launches BEYOND-Alpha, with Chugai Pharmaceutical as First Participant

PR Newswire

Early adopter program aims to scale Ten63's BEYOND platform across challenging pharmaceutical targets

DURHAM, N.C., Nov. 18, 2026 /PRNewswire/ -- Ten63 Therapeutics, Inc. ("Ten63") today announced the launch of BEYOND-Alpha, an early adopter program through which select pharmaceutical companies will work with Ten63 to apply its BEYOND computational drug design platform. Chugai Pharmaceutical Co., Ltd. ("Chugai") is the first pharmaceutical company to participate in the BEYOND-Alpha program.

Ten63 Therapeutics

Through BEYOND-Alpha, a limited number of early participants will work with Ten63 to apply BEYOND across challenging targets. BEYOND-Alpha is designed to allow Ten63's computational design infrastructure to operate across multiple drug discovery programs in parallel.

"AI changes the economics of drug discovery because computational molecular design can scale in a way conventional experimental discovery cannot," said Marcel Frenkel, Ph.D., Co-Founder and CEO of Ten63 Therapeutics. "Scale isn't the only advantage. BEYOND is designed to tackle targets historically considered undruggable or intractable."

As part of BEYOND-Alpha, Ten63 will apply its proprietary computational drug design platform, BEYOND, to Chugai-nominated targets that present challenges for conventional small-molecule discovery approaches. Ten63 will generate and rank molecular structures designed against each target. Chugai will have the right to negotiate terms for the further research, development, and commercialization of molecules including the structures generated by Ten63 against each target, subject to the execution of a separate definitive agreement.

"Chugai is one of the most innovative drug discovery organizations in the world, with an exceptional track record of pursuing new science and challenging therapeutic targets. That makes them an ideal first participant in BEYOND-Alpha," added Frenkel.

Chugai's participation in BEYOND-Alpha expands on the investment from Chugai Venture Fund, the corporate venture arm of Chugai, in Ten63's strategic financing announced in February 2026. 

About BEYOND

BEYOND is Ten63's computational drug design platform for generative chemistry, built to maintain accuracy across low-data and challenging targets. In recent prospective studies across diverse protein targets, BEYOND-generated designs achieved SPR-confirmed hit rates ranging from 11-75%, including against targets for which leading co-folding methods had previously produced few or no confirmed binders. Across these programs, hit identification was achieved by synthesizing and assaying fewer than 20 molecules per program. BEYOND combines high-fidelity physics-based simulation with AI, enabling Ten63 to search in excess of 100 trillion synthetically accessible molecules and design candidates against protein targets long regarded as intractable, including targets lacking conventional binding pockets.

About the BEYOND-Alpha Program

BEYOND-Alpha is Ten63's early adopter drug design program, created to demonstrate the scalability of Ten63's BEYOND platform across pharmaceutical discovery portfolios. It provides a limited number of pharmaceutical participants with the opportunity to apply BEYOND across challenging drug targets. Ten63 applies its computational design technology to generate and prioritize molecular structures against participant-nominated targets, enabling participants to evaluate multiple potential molecular starting points before determining whether to pursue broader development and licensing relationships.

About Ten63 Therapeutics

Ten63 is a frontier AI drug-discovery company spun out of Duke University and TTIC and headquartered in the Research Triangle, North Carolina. Ten63 is leveraging its BEYOND computational platform for generative chemistry to develop first- and best-in-class therapeutics. For more information, visit https://www.ten63tx.com/ and follow us on LinkedIn.

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugai-pharm.co.jp/english/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ten63-therapeutics-launches-beyond-alpha-with-chugai-pharmaceutical-as-first-participant-302944186.html

SOURCE Ten63 Therapeutics